Celltrion said Friday that its biosimilar products for autoimmune diseases are continuing to make an impact, winning bids in key European countries.

First, Celltrion said that Yuflyma won state bids for adalimumab in Friuli-Venezia Giulia (FVG) and Sicilia, Italy, securing to provide Yuflyma for four and a half years in FVG and two years in Sicilia.

Comprising this latest win, Yuflyma has won a total of 12 state tenders in Italy in the last year alone, outperforming its competitors, and being recognized as the most similar biosimilar to the original, AbbVie's Humira. 

Also, Yuflyma continues to win bids in the Netherlands, home to the European Medicines Agency (EMA).

As a result of a win in the adalimumab bid held by Inkoopcombinatie Zuid Oost Nederland (ICZON), the regional drug purchasing organization for the southeastern Netherlands, Yuflyma will be provided to this region for the next three years.

Remicade biosimilar Remsima SC (infliximab) also continued to perform well in Europe, expanding prescriptions.

Following a successful bid for infliximab in the Italian region of Sicily, Remsima will be supplied for two years bringing Remsima's total number of Italian provincial tender wins to six over the past year, strengthening its market presence.

Celltrion also demonstrated the product's competitiveness by winning a bid for Remsima from Inkoopcombinatie Ziekenhuis Apotheken Academische Ziekenhuizen (IZAAZ), a major pharmaceutical purchasing organization in the Netherlands.

IZAAZ is the largest group of university hospitals in the Netherlands and is a key supply channel with influence across the healthcare landscape.

With a 54 percent market share in the Netherlands as of the third quarter of last year, Remsima is the number one prescribed infliximab in the country, bringing more possibilities for Remsima to further stabilize prescribing.

Yoo Won-sik, Head of Europe 3 Department at Celltrion, said that the creation of a unified Celltrion will allow the company to further differentiate its pricing strategy, which will enable Celltrion to continue to make positive performances in the upcoming bids this year.

"As the most similar biosimilar to the original drug, Yuflyma's high-concentration formulation has been recognized for its product competitiveness, including the ability to customize treatment to the patient's situation through dose diversity, which has led to continued prescription expansion in Europe," Yoo went on to say.